The company presented promising Phase II data at the ASCO-GI conference for evorpacept, a drug whose target has been problematic for other drug makers.
Phase II data for ALX Oncology’s evorpacept in gastric cancer raises the possibility that the company can succeed in an immunotherapy field that even some large drug companies have exited due to results that did not meet expectations.
The company presented data on 23 January at the American Society of Clinical Oncology Oncology’s Gastrointestinal Cancers Symposium from the...
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
